EBITDA Growth Due To U.S. Biz Growth: Lupin
  • Gaurav Sarkar
  • Aug 08 2013

Lupin’s stock has gained 38% in the past six months, making it the fifth best performing generic pharma stock globally. Lupin Pharmaceuticals Group President & CEO Vinita Gupta describes the company’s targets, how it plans to improve performance and its strong product pipeline.